Theralytica develops targeted therapeutics that use a lectin‑based delivery system to bind tumor‑associated glycans and modulate cancer stem cell pathways, inducing senescence and reducing invasion. The HOSTILE platform is designed to complement existing chemotherapy and checkpoint inhibitor regimens, helping oncology pharma and CROs overcome resistance and improve treatment efficacy.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer therapies often fail to prevent tumor invasion and resistance, leading to disease progression despite chemotherapy and checkpoint inhibitor treatment.
Solution
Theralytica creates targeted, mechanism-driven therapeutics that intervene in tumor and pathogen ecological interactions to suppress invasion. Its HOSTILE platform (Host‑Oriented Shutdown of Tumor Invasion via Lectin Entry) modulates cancer stemness, induces senescence, and reduces resistance mechanisms, enhancing the efficacy of existing chemo‑ and immunotherapies. The approach is built on mechanistic hypotheses derived from a new understanding of tumor microenvironments and is supported by clinically validated proof‑of‑concept data.
Target Audience
Primary customers are oncology pharmaceutical companies and clinical research organizations seeking novel agents to complement existing chemotherapy and immunotherapy regimens.
Features
- Lectin‑based delivery system that selectively binds tumor‑associated glycans to achieve targeted drug uptake
- Modulation of cancer stem cell pathways to diminish self‑renewal and invasive potential
- Induction of cellular senescence to halt tumor proliferation and sensitize cells to standard therapies
- Combination strategy that lowers resistance to chemotherapy and checkpoint inhibitor regimens
- Preclinical and early clinical validation demonstrating target engagement and anti‑invasion activity